Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

Wednesday, October 23, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the clinical results from a Phase 1 trial of PRT3789, a novel intravenous SMARCA2 degrader. This treatment is aimed at patients with advanced solid tumors harboring a SMARCA4 mutation. The trial's findings suggest that PRT3789 could offer a new therapeutic avenue for this patient population.
Price reaction · baseline $1.585 (2024-10-23T18:02:00.000Z) · hit during market hours · 2 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-class intravenous SMARCA2 degrader shows promise.
  • Clinical results indicate potential for advanced solid tumors.
  • Targeting SMARCA4 mutation may provide new treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Timothy A Yap, Afshin Dowlati, Ibiayi Dagogo-Jack, Julien Vibert, Alexander I Spira, Victor Moreno, Salman R Punekar, Emiliano Calvo, Guru P Sonpavde, Mark Awad, Jonathan W Riess, Tatiana Hernández-Guerrero, Benjamin Herzberg, Antoine Italiano, Aurelie Swalduz, Ticiana A Leal, Joseph C Murray, David SP Tan, Patricia LoRusso, Egbert F Smit, Edward B Garon, William Novotny, Robin Guo

Frequently Asked Questions

What is PRT3789?

PRT3789 is a first-in-class intravenous SMARCA2 degrader designed for treating advanced solid tumors.

What type of mutation does PRT3789 target?

PRT3789 specifically targets the SMARCA4 mutation in patients.

What were the results of the Phase 1 trial?

The Phase 1 trial of PRT3789 indicated promising clinical results for patients with advanced solid tumors.

Who conducted the Phase 1 trial?

The trial was conducted by a team of researchers including Timothy A Yap and Afshin Dowlati.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 SMARCA4 mutation advanced solid tumors Phase 1 trial
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →